^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the NCCN melanoma panel agrees that nivolumab should be listed as an adjuvant postoperative treatment option for patients with stage III-IV at presentation, as well as for patients with recurrent stage III/IV disease.
